FDA committee backs GSK’s multiple myeloma drug
If approved, belantamab mafodotin will be a first-in-class anti-BCMA therapy for relapsed/refractory multiple myeloma
Read More
Tag: ODAC
FDA panel backs Novartis’ CAR-T therapy CTL019
Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
